WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Cell and Gene Therapy
Mekonos, Inc. | November 10, 2021
Mekonos, a biotech company building the future of cell therapies on a chip, has raised $25M in an oversubscribed Series A round co-led by Reimagined Ventures, Fiscus Ventures, and PEAK6 Strategic Capital, a division of PEAK6 Investments. New institutional and strategic investors, including Section 32, Sands Capital, TDK Ventures, and the venture arm of Debiopharm, and previous investors, including Novartis Pharma AG (dRx Capital) and Elementum Ventures, also joined in the funding round that will...
LUMICKS | May 26, 2022
LUMICKS, a leading life science tools company that develops instruments for dynamic single-molecule and cell avidity analysis, today announced the publication in Cancer Cell of preclinical research identifying "Avidity Enhancement" as a new strategy to improve therapeutic outcome of Chimeric Antigen Receptor (CAR) T cell immunotherapy in Acute Myeloid Leukemia (AML).
AML poses significant clinical challenges due to its resistance to therapies and its bleak prognosi...
Aruna Bio | June 01, 2022
Aruna Bio, Inc., a leader in the development of neural exosome based therapeutics for the treatment of neurodegenerative diseases, today announced that it has received funding from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health of Health to advance AB126™, a multimodal neuroprotective and regenerative neural stem cell extracellular vesicle (NSC EV) product, to treat Traumatic Brain Injury (TBI).
Genscript | August 18, 2022
GenScript USA Inc., the world's leading life-science research tools and services provider, announced the availability of a new research use only and pre-clinical messenger RNA synthesis service for biopharma research and development teams. By applying decades of experience in molecular biology, GenScript now offers a single-vendor gene-to-mRNA service that delivers custom mRNA within six to eight weeks.
mRNA provides new therapeutic opportunities for a range of diseases, and s...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE